NCT06902545 - A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer. | Biotech Hunter

Enrollment

377

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2030

Conditions

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or CancerMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG

zolbetuximab

Intravenous

Trial Locations (10)

Unknown

RECRUITING

KR82010, Goyang-si

RECRUITING

KR82008, Suwon

RECRUITING

KR82006, Yangsan

RECRUITING

KR82012, Hwasun Gun

RECRUITING

KR82001, Seoul

RECRUITING

KR82002, Seoul

RECRUITING

KR82003, Seoul

RECRUITING

KR82004, Seoul

RECRUITING

KR82005, Seoul

RECRUITING

KR82011, Seoul

All Listed Sponsors

lead

Astellas Pharma Korea, Inc.

INDUSTRY